Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option

Go back to Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option
(NASDAQ: FRNM) Delayed: 14.01 -0.05 (0.36%)
Previous Close $14.06    52 Week High $ 
Open $14.14    52 Week Low $ 
Day High $14.42    P/E N/A 
Day Low $13.92    EPS $ 
Volume 381,706